2024
Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival
Zaman S, Gorelick F, Chrobrutskiy A, Chobrutskiy B, Desir G, Blanck G. Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival. Oncotarget 2024, 15: 550-561. PMID: 39102218, PMCID: PMC11299663, DOI: 10.18632/oncotarget.28633.Peer-Reviewed Original ResearchConceptsT cell receptorOverall survivalT cellsAssociated with improved overall survivalT-cell receptor CDR3sPromote T cell activationImproved overall survivalSurvival of melanomaPancreatic cancer patientsT cell activationT cell receptor recognitionTumor-residentTumor rejectionMelanoma patientsMelanoma growthMelanoma survivalImmune signature genesSurvival associationsCancer patientsMelanomaSignature genesAmino acid sequenceSurvivalPatientsExpression levels
2023
Specific Intratumor Bacteria Genera and TRG Recombinations Associated with Greater Survival Probability in Alimentary Tract Cancers
Zaman S, Chobrutskiy B, Quach J, Blanck G. Specific Intratumor Bacteria Genera and TRG Recombinations Associated with Greater Survival Probability in Alimentary Tract Cancers. Journal Of Gastrointestinal Cancer 2023, 54: 1300-1307. PMID: 37103748, DOI: 10.1007/s12029-023-00935-2.Peer-Reviewed Original ResearchConceptsT-cell infiltratesStomach adenocarcinomaGamma delta T cellsCox proportional hazards modelAlimentary tract cancersTumor immune milieuProportional hazards modelPrimary tumor samplesImmune milieuOS probabilityCancer Genome AtlasCell infiltrateTract cancerPatient survivalEsophageal cancerPrimary tumorCancer DatabaseT cellsHazards modelTumor samplesExome filesAlimentary tractGenome AtlasBacterial infiltrationInfiltratesBacterial Sequencing Reads in Blood Exome Files from Melanoma and Cervical Cancer Patients are Associated with Cancer Recurrence
Quach J, Diaz M, Huda T, Kinskey J, Zaman S, Desantis J, Cios K, Blanck G. Bacterial Sequencing Reads in Blood Exome Files from Melanoma and Cervical Cancer Patients are Associated with Cancer Recurrence. Molecular Biotechnology 2023, 65: 1476-1484. PMID: 36653589, DOI: 10.1007/s12033-023-00663-9.Peer-Reviewed Original ResearchConceptsCervical cancer casesCervical cancer patientsCancer patientsExome filesCancer recurrenceCancer casesDisease-free survival probabilityImmunocompromised Cancer PatientsOverall survival resultsCancer clinical outcomesBacterial blood infectionsLower DFSClinical outcomesCervical cancerPrimary tumorSurvival resultsMelanoma casesBlood infectionSolid tumorsGreater riskPatientsBacteroides fragilisBloodPresence of bacteriaBacteroides species
2022
TCR gene segment usage and HLA alleles that are associated with cancer survival rates also represent racial disparities
Angelakakis G, Serraneau K, Barker V, Callahan B, Tong W, Zaman S, Huda T, Blanck G. TCR gene segment usage and HLA alleles that are associated with cancer survival rates also represent racial disparities. International Journal Of Immunogenetics 2022, 50: 41-47. PMID: 36585798, DOI: 10.1111/iji.12610.Peer-Reviewed Original ResearchConceptsTCR gene segment usageHLA allele combinationsGene segment usageCancer outcomesRacial disparitiesSegment usageHLA allelesCertain HLA allelesCancer survival ratesDistinct survival outcomesSocioeconomic factorsDisease courseSurvival outcomesInfectious disease courseSurvival rateAllele combinationsDifferent racial groupsGenetic polymorphismsPrevious pathogen exposurePathogen exposureOutcomesRacial groupsDisparitiesFactorsCancerChemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE vaccine auto-reactivity
Eakins R, Chobrutskiy A, Teer J, Patel D, Hsiang M, Huda T, Zaman S, Sexton W, Coppola D, Falasiri S, Blanck G, Chobrutskiy B. Chemical complementarity between tumor resident, T-cell receptor CDR3s and MAGEA3/6 correlates with increased melanoma survival: Potential relevance to MAGE vaccine auto-reactivity. Molecular Immunology 2022, 150: 58-66. PMID: 35987136, DOI: 10.1016/j.molimm.2022.08.001.Peer-Reviewed Original Research
2021
High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer
Chobrutskiy BI, Chobrutskiy A, Zaman S, Yeagley M, Huda TI, Blanck G. High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer. Molecular Immunology 2021, 135: 247-253. PMID: 33933816, DOI: 10.1016/j.molimm.2021.02.026.Peer-Reviewed Original ResearchSystemic Adaptive Immune Parameters Associated with Neuroblastoma Outcomes: the Significance of Gamma-Delta T Cells
Gozlan EC, Chobrutskiy BI, Zaman S, Yeagley M, Blanck G. Systemic Adaptive Immune Parameters Associated with Neuroblastoma Outcomes: the Significance of Gamma-Delta T Cells. Journal Of Molecular Neuroscience 2021, 71: 2393-2404. PMID: 33666857, DOI: 10.1007/s12031-021-01813-x.Peer-Reviewed Original ResearchConceptsGamma delta T cellsImmune receptor recombinationsAdaptive immune responsesT cellsImmune responseLower overall survival rateSet of neuroblastomaSystemic immune stateOverall survival rateAdaptive immune parametersImmunology parametersActive diseaseDevelopment of cancerYounger patientsImmune parametersImmune stateCancer evaluationNeuroblastoma outcomeSurvival rateImmunity developmentYounger ageTumor samplesAntigenic specificityImmune receptorsReceptor geneSpecific HLA alleles, paired with TCR V- and J-gene segment usage, link to distinct multiple myeloma survival rates
Huda TI, Mihyu M, Gozlan EC, Arndt MF, Diaz MJ, Zaman S, Chobrutskiy BI, Blanck G. Specific HLA alleles, paired with TCR V- and J-gene segment usage, link to distinct multiple myeloma survival rates. Leukemia & Lymphoma 2021, 62: 1711-1720. PMID: 33622167, DOI: 10.1080/10428194.2021.1885655.Peer-Reviewed Original ResearchConceptsHLA allele combinationsTCR VBlood samplesSurvival rateT cell receptor VOverall survival rateT cell characterizationSpecific HLA allelesLarger patient setsDistinct overall survival ratesSolid tumor typesSurvival distinctionsMM cohortHLA allelesJ-gene segment usageTumor typesPotential associationImmunogenomics studiesHLASegment usagePatient setAllele combinationsTCR recombinationImmunogenetic parametersImmunogenomic dataReconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response
Hajiran A, Chakiryan N, Aydin A, Zemp L, Nguyen J, Laborde J, Chahoud J, Spiess P, Zaman S, Falasiri S, Fournier M, Teer J, Dhillon J, McCarthy S, Moran-Segura C, Katende E, Sexton W, Koomen J, Mulé J, Kim Y, Manley B. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clinical & Experimental Immunology 2021, 204: 96-106. PMID: 33346915, PMCID: PMC7944355, DOI: 10.1111/cei.13567.Peer-Reviewed Original ResearchConceptsMetastatic clear cell renal cell carcinomaClear cell renal cell carcinomaTumor immune microenvironmentRenal cell carcinomaT-betOverall survivalCell carcinomaMetastatic renal cell carcinomaForkhead box protein 3Improved overall survivalCell renal cell carcinomaCox regression analysisImmune cell distributionT-cell markersPoor overall survivalBox protein 3Tumor-stromal interfaceMetastatic tumor samplesPrecision treatment strategiesTumor-stroma interfaceTumor coreImproved survivalImmune markersImmunotherapy responsePoor outcome
2020
Chemical features of blood-borne TRG CDR3s associated with an increased overall survival in breast cancer
Chobrutskiy A, Chobrutskiy BI, Zaman S, Hsiang M, Blanck G. Chemical features of blood-borne TRG CDR3s associated with an increased overall survival in breast cancer. Breast Cancer Research And Treatment 2020, 185: 591-600. PMID: 33180235, DOI: 10.1007/s10549-020-05996-6.Peer-Reviewed Original ResearchConceptsOverall survivalBreast cancerPrimary breast cancer patientsGamma delta T cellsBreast cancer tumor tissuesBreast cancer settingProgesterone receptor statusBreast cancer patientsGreater overall survivalPotential antigenic targetsCancer tumor tissuesPatient ageReceptor statusCancer patientsAntigenic targetsCancer settingT cellsSurvival correlationB cellsSurvival rateTumor tissueHigher survival rateImmunogenomic approachesConclusionsThese resultsSurvival parametersTRBV and TRBJ usage, when paired with specific HLA alleles, associates with distinct head and neck cancer survival rates
Arndt MF, Koohestani DM, Chobrutskiy BI, Mihyu MM, Diaz M, Gozlan EC, Yeagley M, Zaman S, Roca AM, Blanck G. TRBV and TRBJ usage, when paired with specific HLA alleles, associates with distinct head and neck cancer survival rates. Human Immunology 2020, 81: 692-696. PMID: 32950267, DOI: 10.1016/j.humimm.2020.08.007.Peer-Reviewed Original ResearchMeSH KeywordsAllelesBiomarkers, TumorDisease-Free SurvivalExomeGenes, T-Cell Receptor betaHead and Neck NeoplasmsHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA AntigensHumansKaplan-Meier EstimatePrognosisReceptors, Antigen, T-Cell, alpha-betaSurvival RateV(D)J RecombinationConceptsHuman papilloma virusHLA allele combinationsT cell receptorSurvival rateCervical cancerHLA allelesParticular human leukocyte antigen (HLA) allelesBetter disease-free survival rateCancer Genome Atlas (TCGA) headDisease-free survival ratesJ usageHuman leukocyte antigen (HLA) allelesFree survival rateOverall survival rateCancer survival ratesSpecific HLA allelesDistinct overall survival ratesNeck cancer datasetPapilloma virusIndependent associationAntigen presentationAntigen allelesViral infectionHLAExome filesImmunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members
Diaz MJ, Chobrutskiy BI, Zaman S, Blanck G. Immunogenomics of colorectal adenocarcinoma: Survival distinctions represented by immune receptor, CDR3 chemical features and high expression of BTN gene family members. Cancer Treatment And Research Communications 2020, 24: 100196. PMID: 32769037, DOI: 10.1016/j.ctarc.2020.100196.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAftercareAntineoplastic Agents, ImmunologicalBiomarkers, TumorButyrophilinsColorectal NeoplasmsComplementarity Determining RegionsComputational BiologyDisease-Free SurvivalExomeGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateReceptors, Antigen, B-CellReceptors, Antigen, T-CellRecombination, GeneticRNA-SeqSurvival RateConceptsSurvival rateLung cancerColon cancerImmune receptor recombinationsWorse survival rateCancer survival ratesCases of melanomaBetter survival rateB cell receptorFamily membersSurvival distinctionsCancer Genome AtlasImmunotherapy approachesColorectal adenocarcinomaT cellsImmunogenomics studiesCancer typesCancerConsistent associationHigh expressionGenome AtlasImmune receptorsImmunogenomic featuresMelanomaCancer exomesAntiviral T Cell Receptor Complementarity Determining Region-3 Sequences Are Associated with a Worse Cancer Outcome: A Pancancer Analysis
Zaman S, Chobrutskiy BI, Patel JS, Diviney A, Tu YN, Tong WL, Gill T, Blanck G. Antiviral T Cell Receptor Complementarity Determining Region-3 Sequences Are Associated with a Worse Cancer Outcome: A Pancancer Analysis. Viral Immunology 2020, 33: 404-412. PMID: 32315578, DOI: 10.1089/vim.2019.0156.Peer-Reviewed Original ResearchConceptsT cellsRegion 3 sequencesSurvival rateTissue-resident T cellsCancer typesImmune receptor recombinationsResident T cellsWorse survival rateHuman papilloma virusWorse cancer outcomesTCGA data setsThymus cancerCancer Genome AtlasViral etiologyCancer outcomesDistinct survival ratesNeck cancerPapilloma virusDifferent cancer typesSolid tumorsTumor samplesExome filesGenome AtlasPancancer AnalysisCancerA scoring system for the electrostatic complementarities of T‐cell receptors and cancer‐mutant amino acids: multi‐cancer analyses of associated survival rates
Chobrutskiy BI, Yeagley M, Diviney A, Zaman S, Gozlan EC, Tipping P, Koohestani DM, Roca AM, Blanck G. A scoring system for the electrostatic complementarities of T‐cell receptors and cancer‐mutant amino acids: multi‐cancer analyses of associated survival rates. Immunology 2020, 159: 373-383. PMID: 31821535, PMCID: PMC7077996, DOI: 10.1111/imm.13165.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsAmino Acid SequenceAmino AcidsAntigens, NeoplasmBinding SitesBreast NeoplasmsComplementarity Determining RegionsExomeFemaleGene ExpressionHumansLung NeoplasmsMaleMutationPrognosisProtein BindingReceptor-CD3 Complex, Antigen, T-CellResearch DesignSkin NeoplasmsStatic ElectricitySurvival RateT-LymphocytesConceptsT cell receptorImmune systemSurvival rateAnti-tumor immune responseTumor-infiltrating lymphocytesNeo-antigensPeptide vaccineImmune responseTumor antigensTumor specimensTumor specimenScoring systemStem cell proteinsHigher survival rateMutant amino acidsReceptorsAmino acidsMutant peptidesAa sequencesCell proteinsLymphocytesVaccineImmunoscoringAntigenSpecific genes
2019
Aberrant Epidermal Growth Factor Receptor RNA Splice Products Are Among the Most Frequent Somatic Alterations in Clear Cell Renal Cell Carcinoma and Are Associated with a Poor Response to Immunotherapy
Zaman S, Hajiran A, Coba GA, Robinson T, Madanayake TW, Segarra DT, Chobrutskiy BI, Boyle TA, Zhou JM, Kim Y, Mulé JJ, Teer JK, Manley BJ. Aberrant Epidermal Growth Factor Receptor RNA Splice Products Are Among the Most Frequent Somatic Alterations in Clear Cell Renal Cell Carcinoma and Are Associated with a Poor Response to Immunotherapy. European Urology Focus 2019, 7: 373-380. PMID: 31901438, PMCID: PMC7771328, DOI: 10.1016/j.euf.2019.12.001.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCell renal cell carcinomaClear cell renal cell carcinomaCell carcinomaPoor responseAdvanced clear cell renal cell carcinomaTumor tissueNon-RCC tumorsCohort of patientsRCC tumor tissuesReverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionFrequent somatic alterationsKidney cancer cell linesAdvanced ccRCCCancer cell linesCancer Genome AtlasSystemic therapyClinical outcomesInstitutional cohortPatient populationPoor prognosisHuman kidney cancer cell linesClinical significanceTCGA cohortChemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma
Chobrutskiy BI, Yeagley M, Tipping P, Zaman S, Diviney A, Patel DN, Falasiri S, Uversky VN, Blanck G. Chemical complementarity between immune receptor CDR3s and IDH1 mutants correlates with increased survival for lower grade glioma. Oncogene 2019, 39: 1773-1783. PMID: 31740784, DOI: 10.1038/s41388-019-1101-2.Peer-Reviewed Original ResearchConceptsLow-grade gliomasComplementarity-determining region 3T cell receptor beta chainImmune responseGrade gliomasIDH1 mutantChronic inflammationReceptor beta chainCancer immunologyLGG prognosisNRAS mutantsSurvival rateCancer developmentCDR3 domainsGliomasImmune receptorsBeta chainAnticancer processesSurvivalPotential MMP2-mediated availability of HLA binding, mutant ECM peptides reflects better melanoma survival rates and greater T-cell infiltrates
Zaman S, Chobrutskiy BI, Patel JS, Callahan BM, Mihyu MM, Diviney A, Blanck G. Potential MMP2-mediated availability of HLA binding, mutant ECM peptides reflects better melanoma survival rates and greater T-cell infiltrates. Laboratory Investigation 2019, 99: 1287-1295. PMID: 31019293, DOI: 10.1038/s41374-019-0248-3.Peer-Reviewed Original ResearchConceptsMutant amino acidsAmino acidsStructural proteinsExtracellular matrix structural proteinsMatrix metalloproteinase-2Cancer progressionLate-stage cancer developmentMutant peptidesECM structural proteinsMatrix structural proteinsBioinformatics approachProtein mutantsProtease functionECM peptidesSuch proteasesMutantsPotential substratesCancer developmentProteaseMelanoma samplesProteinSpread of cancerTumor samplesMetalloproteinase-2Cancer microenvironmentA brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer
Costa R, Zaman S, Sharpe S, Helenowski I, Shaw C, Han H, Soliman H, Czerniecki B. A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer. Drug Design Development And Therapy 2019, 13: 309-316. PMID: 30679903, PMCID: PMC6338114, DOI: 10.2147/dddt.s188925.Peer-Reviewed Original ResearchConceptsChills/rigorsInjection site reactionsAbsolute riskAdverse eventsHER2 vaccinesSite reactionsTreatment-related serious adverse eventsLarge-scale prospective clinical trialsGrade 3/4 adverse eventsAvailable clinical trial dataHuman epidermal growth factor receptor 2Left ventricle ejection fractionEpidermal growth factor receptor 2Treatment-related deathsSerious adverse eventsGrowth factor receptor 2Prospective clinical trialsVentricle ejection fractionModest clinical efficacyTreatment of patientsClinical trial dataFactor receptor 2Adequate safety assessmentEvidence of heterogeneityGrade fatigue
2018
T-cell receptor-α CDR3 domain chemical features correlate with survival rates in bladder cancer
Chobrutskiy BI, Zaman S, Diviney A, Mihyu MM, Blanck G. T-cell receptor-α CDR3 domain chemical features correlate with survival rates in bladder cancer. Journal Of Cancer Research And Clinical Oncology 2018, 145: 615-623. PMID: 30539280, DOI: 10.1007/s00432-018-2815-1.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesT cell responsesBladder tumor tissuesT-cell featuresEx vivo amplificationT cell receptorBladder cancerCancer findingsFavorable outcomeCancer settingBetter outcomesSurvival rateTumor tissueCancerDriver mutationsImmunotherapyBiochemical featuresBioinformatics assessmentOutcomesAntigen bindingRegion 3TILsPatientsLymphocytesTherapyMAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma
Zaman S, Chobrutskiy BI, Blanck G. MAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma. Cell Cycle 2018, 17: 2474-2483. PMID: 30394813, PMCID: PMC6342068, DOI: 10.1080/15384101.2018.1542898.Peer-Reviewed Original ResearchConceptsMAPT expressionGene expressionProliferation-effector genesHuman Genome OrganizationContext of tauopathyH2A histone familyCaspase-9 genesOvarian cancerPediatric neuroblastomaGenome organizationCaspase-3 geneCancer Genome AtlasHistone familyKaplan-Meier survival curvesProtein geneTransactive response DNA binding protein 43Neuronal degenerative diseasesType 1 geneDNA binding protein 43Expression of apoptosisAmyloid precursor protein geneGenesPrecursor protein geneAmyotrophic lateral sclerosisNeuronal cells